Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies

We explored the molecular evolution of the spike gene after the administration of anti-spike monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the 13 patients acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as a mixture without cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Jary, Aude, Marot, Stéphane, Faycal, Antoine, Leon, Sacha, Sayon, Sophie, Zafilaza, Karen, Ghidaoui, Emna, Quoc, Stéphanie Nguyen, Nemlaghi, Safaa, Choquet, Sylvain, Dres, Martin, Pourcher, Valérie, Calvez, Vincent, Junot, Helga, Marcelin, Anne-Geneviève, Soulié, Cathia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877338/
https://www.ncbi.nlm.nih.gov/pubmed/35215820
http://dx.doi.org/10.3390/v14020226
Descripción
Sumario:We explored the molecular evolution of the spike gene after the administration of anti-spike monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the 13 patients acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as a mixture without clinical impact, while the Q493R mutation emerged in two patients (one receiving bamlanivimab and one receiving bamlanivimab/etesevimab) with fatal outcomes. Careful virological monitoring of patients treated with mAbs should be performed, especially in immunosuppressed patients.

Ejemplares similares